iwCLL 2023

2023 iwCLL Program Agenda

This agenda has been prepared to provide information regarding the upcoming meeting and is subject to change.

Friday, October 6
7:30 AM
YIM Continental Breakfast
8:00 AM
Young Investigator Meeting

6:30 PM

iwCLL Welcome Reception
Saturday, October 7, 2023
7:15 AM
Continental Breakfast
8:15 AM
Welcome and Introductions
Jennifer Brown, MD, PhD
8:30 AM

Honoring the Past: In Memoriam and 20 Years of iwCLL 

Session 1: Integrative Aspects of Genomics

Session Co-Chairs: Christopher Oakes, MD, PhD & Gad A. Getz, PhD

8:40 AM
Multiomic Integration in CLL
Cynthia K. Hahn, MD
8:55 AM
Whole-Genome Analysis of CLL and Interplay of Coding, Non-Coding, Transcriptome and Epigenetic Events
Pauline Robbe, PhD
9:10 AM
Genomics of Richter Transformation: Part I
Ferran Nadeu, PhD
9:20 AM
Genomics of Richter Transformation: Part II
Erin Parry, MD, PhD
9:30 AM
Commentary on Each Other’s Work and Consensus Regarding the Genomics and Richter’s Transformation
Ferran Nadeu, PhD and Erin Parry, PhD
9:40 AM
Panel Discussion With Interactivity and Audience Q&A
9:50 AM
*SF3B1 mutation and ATM deletion co-drive leukemogenesis via centromeric R-loop dysregulation
Lili Wang, MD, PhD
10:00 AM
*Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
Qu Jiang, PhD
10:10 AM
Morning Break
Session 2: Proteomics and Metabolism of CLL
Session Co-Chairs: Catherine Wu, MD & Jennifer Abelin, PhD
10:35 AM
Influence of Metabolism on Leukemia Progression
Matthew Vander Heiden, MD, PhD

10:50 AM

Proteogenomic Characterization of CLL and Drug Response/Resistance
Sascha Dietrich, MD
11:05 AM
CLL Proteomics and Immunoproteomics
Catherine Wu, MD
11:20 AM
*Targeting translation initiation as novel therapeutic in CLL

Etienne Moussay, PhD

11:30 AM
*METTL3 contributes to aggressive CLL via post-transcriptional regulation of splicing factor

Lili Wang, MD, PhD

11:40 AM

*TRAF3 inactivation in chronic lymphocytic leukemia enhances metabolic cellular plasticity through metabolic reprogramming and associates with adverse prognosis

Claudia Pérez Carretero, PhD

11:50 AM
Panel Discussion With Interactivity and Audience Q&A

12:05 PM

Lunch
12:55 PM
Industry Supported Symposium
Session 3: Microenvironment and Pre-Clinical Immunotherapies
Session Co-Chairs: Adrian Wiestner, MD, PhD & Silvia Deaglio, MD, PhD
1:55 PM
Anti-Tumor Immunity in the Lymphoid Microenvironment
Martina Seiffert, PhD
2:10 PM
The Tumor Supportive Microenvironment of CLL
Jérôme Paggetti, PhD
2:25 PM
Modeling the Tumor Microenvironment of CLL In Vitro
Cristina Scielzo, PhD
2:35 PM
The Tumor Microenvironment and Genetic Heterogeneity of CLL
Clare Sun, MD
2:45 PM
Panel Discussion With Interactivity and Audience Q&A
3:05 PM
*Constitutive VLA-4 activation is linked to BCR autonomous signaling in circulating CLL cells and promotes pro-survival signals through soluble blood-borne VCAM-1 binding
Erika Tissino, PhD

3:15 PM

*Exploiting the modulation of FOXO1 signaling as a therapeutic target in CLL through combination of ERK and BTK inhibition
Jodie F. Hay, PhD
3:25 PM
Afternoon Break
Session 4: Debate and Roundtable – How Do We Define Success in CLL?
Session Co-Chairs: John Seymour, MBBS, PhD & Lydia Scarfò, PhD

3:50 PM

*Does the Life Expectancy of Elderly CLL Patients Receiving Upfront Targeted Agents Approach the Life Expectancy of the General Population?

Stefano Molica, MD

4:00 PM
Multiparty “Statement of Perspective”

Michele Nadeem Baker
Danielle Brander, MD
Barbara Eichhorst, MD
Carsten Niemann, MD, PhD
William Wierda, MD, PhD 

4:35 PM
Panel Discussion With Interactivity and Audience Q&A
5:10 PM
iwCLL Update
Thomas J. Kipps, MD, PhD
5:25 PM
Adjourn
End of Day 1
* = Oral Presentation
** = Poster Presentation
*** = Late Breaker Poster Presentation
Sunday, October 8
7:15 AM
Continental Breakfast
Session 5: Optimizing Initial Therapy of CLL
Session Co-Chairs: Matthew Davids, MD, MMSc & Mazyar Shadman, MD, MPH
8:15 AM
The Role Today of Continuous BTK Inhibitors
Kerry Rogers, MD
8:30 AM
Updated Perspective on Time-Limited Venetoclax + Obinutuzumab
Othman Al-Sawaf, MD
8:45 AM
Current and Future Use of BTKi + BCL-2i Combinations
Nitin Jain, MD
9:00 AM
Panel Discussion With Interactivity and Audience Q&A
9:15 AM
Trials in Progress
9:15 AM
*Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group
Florian Simon, MD
9:25 AM
*Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk: interim results of MRD kinetics in the ERADIC trial from the FILO group
Anne-Sophie Michallet, MD, PhD
9:35 AM
*Bruton tyrosine kinase inhibitor ibrutinib induces hypertension by upregulating transcription of CaV1.2 calcium channel
Juejin Wang, MD, PhD
9:45 AM
*Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment
Andy Rawstron, PhD
9:55 AM
Morning Break
10:20 AM
Industry Supported Symposium
Session 6: Mechanisms of Resistance

Session Co-Chairs: Jennifer Woyach, MD & Marek Mráz, PhD

11:20 AM
Resistance to Covalent BTKi
Adrian Wiestner, MD, PhD
11:35 AM
Resistance to Non-Covalent BTKi
Varsha Gandhi, MD
11:50 AM
Resistance to BCL2i

Rachel Thijssen, PhD

12:05 PM

*Bruton’s Tyrosine Kinase and Phospholipase C-Gamma 2 Mutational Profiles in Pooled Analysis of Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Inhye Ahn, MD
12:15 PM
*Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia (CLL)
Kiyomi Mashima, MD, PhD
12:25 PM
*Recurrent Genomic Alterations in the Apoptotic Machinery in Patients With CLL Treated With Venetoclax Monotherapy Following Treatment With BCRi
Jennifer Woyach, MD
12:35 PM
**Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Jennifer Brown, MD, PhD

12:40 PM

Panel Discussion With Interactivity and Audience Q&A

12:55 PM
Lunch
1:45 PM
Industry Supported Symposium
Session 7: Future Directions for the Treatment of Relapsed/Refractory CLL
Session Co-Chairs: Arnon Kater, MD, PhD & Danielle Brander, MD

2:45 PM

*Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the Phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort
Arnon Kater, MD, PhD

2:55 PM

*Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)
Paula Cramer, MD

3:05 PM

**Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
John F. Seymour, MBBS, FRACP, PhD

3:10 PM

**Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Tanya Siddiqi, MD
3:15 PM
BTK Degraders – From Bench To Bedside
Alexey Danilov, MD, PhD
3:25 PM
Novel Inducers of Apoptosis
Deepa Sampath, PhD
3:35 PM
How to Overcome T-Cell Dysfunction: Bispecifics
Arnon Kater, MD, PhD
3:45 PM
How to Overcome T-Cell Dysfunction: Cellular Therapies
Jos Melenhorst, PhD
3:55 PM
Panel Discussion with Interactivity and Audience Q&A
4:10 PM
Binet/Rai Medal Presentation
4:20 PM
General Session Adjourns

4:30 PM

Wine & Cheese Poster Session and Reception
* = Oral Presentation
** = Poster Presentation
*** = Late Breaker Poster Presentation
End of Day 2
Monday, October 9
7:15 AM
Continental Breakfast
Session 8: Richter Transformation – From Biology to Clinic

Session Co-Chairs: Inhye Ahn, MD & Lili Wang, MD, PhD

8:15 AM
In Vivo Modeling of CLL Transformation: PDX Model
Silvia Deaglio, MD, PhD
8:25 AM
In Vivo Modeling of CLL Transformation: Multiplex In Vivo CRISPR Editing

Elisa ten Hacken, PhD

8:35 AM
In Vivo Modeling of CLL Transformation: TP53 and CDKN2a/b Model
Dimitar Efremov, MD, PhD
8:45 AM
Panel Discussion on In Vivo Modeling

8:55 AM

*Mitochondrial dysregulation and metabolite imbalance in Richter Transformation: Insights from a mouse model
Prajish S. Iyer, PhD

9:05 AM

*Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Niamh Appleby, MRCPI FRCPath

9:10 AM

***Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter Transformation
Heribert Playa-Albinyana, BSc, MSc

9:15 AM

Chemoimmunotherapy and BCR-Targeted Agents for Richter Transformation
Sameer Parikh, MBBS
9:25 AM
Investigational Therapies for Richter Transformation: Bispecifics
Philip Thompson, MBBS
9:35 AM
Investigational Therapies for Richter Transformation: Cellular Therapies
Tanya Siddiqi, MD
9:45 AM
Panel Discussion with Interactivity and Audience Q&A
9:55 AM
Morning Break
Session 9: Immunodeficiency and Infections in Patients with CLL
Session Co-Chairs: Carsten Niemann, MD, PhD & Clare Sun, MD
10:15 AM
General Management of CLL patients from a Vaccine and Prophylaxis Standpoint
Carolyn Owen, MD

10:30 AM

What Can We Learn from COVID-19 About Immune Dysfunction and Risk of Infections in CLL?
Yair Herishanu, MD

10:45 AM

CLL Vaccine Responsiveness
Chris Pleyer, MD
11:00 AM
Panel Discussion with Interactivity and Audience Q&A
11:15 AM
*Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with targeted drugs: pooled analysis of clinical trials from the German CLL Study Group (GCLLSG)
Elia Boccellato, MD
11:25 AM
*Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia
Randall S. Davis, MD
11:35 AM
Industry Supported Symposium

12:35 PM

Lunch

1:25 PM

Keynote Anticipated Role of AI/Machine Learning in Research and Treatment of CLL and Other Malignancies
Mihaela van der Schaar, PhD
Session 10: Global Perspective on CLL Management – Real World Data and Patient Experiences
Session Co-Chairs: Anna Schuh, MD, PhD & Pat Garcia-Gonzalez

1:55 PM

Special Announcement From the iwCLL
Anna Schuh, MD, PhD

2:00 PM

The Impact of the War on Management of Patients with CLL in Ukraine: What can the iwCLL do to Mitigate Impact in Short and Longer Term
Iryna Kriachok, PhD

2:10 PM

Managing Patients with CLL from Different Socio-Economic Backgrounds in Argentina
Miguel Pavlovsky, MD

2:20 PM

Update on the iwCLL Capacity Building Pilot Program in Tanzania
William Frank Mawalla, MD

2:30 PM

Challenges of Diagnosis and Management of Patients with CLL in South Korea
Ja Min Byun, MD, PhD

2:40 PM

Trial Updates from China
Shenmiao Yang, MD

2:50 PM

Global Survey Results from the CLL Advocates Network
Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd

3:00 PM

*A high proportion of IGHV4-39, subset #8 and #8B in Chinese patients with chronic lymphocytic leukemia: a retrospective analysis of 3154 Ig VH sequences by cwCLL, Chinese workshop on CLL
Yi Xia, MD

3:10 PM

Panel Discussion With Interactivity and Audience Q&A

3:25 PM

Afternoon Break
Session 11: Past, Present, and Future of CLL
Session Chair: Jennifer R. Brown, MD, PhD

3:50 PM

Future Research Priorities and Unmet Needs in CLL: A Roundtable Discussion and Audience Q&A
Jennifer R. Brown, MD, PhD
Florence Cymbalista, MD, PhD
Matthew Davids, MD, MMSc
Paolo Ghia, MD, PhD
Thomas J. Kipps, MD, PhD
Susan O’Brien, MD

4:55 PM

Closing Comments/iwCLL 2023 Awards/2025 Announcement

Jennifer R. Brown, MD, PhD

5:10 PM

Close of Workshop
* = Oral Presentation
** = Poster Presentation
*** = Late Breaker Poster Presentation